Bridging neurocognitive aging and disease modification: targeting functional mechanisms of memory impairment

Curr Alzheimer Res. 2010 May;7(3):197-9. doi: 10.2174/156720510791050867.

Abstract

Risk for Alzheimer's disease escalates dramatically with increasing age in the later decades of life. It is widely recognized that a preclinical condition in which memory loss is greater than would be expected for a person's age, referred to as amnestic mild cognitive impairment, may offer the best opportunity for intervention to treat symptoms and modify disease progression. Here we discuss a basis for age-related memory impairment, first discovered in animal models and recently isolated in the medial temporal lobe system of man, that offers a novel entry point for restoring memory function with the possible benefit in slowing progression to Alzheimer's disease.

Publication types

  • Review

MeSH terms

  • Aged
  • Aging / physiology
  • Aging / psychology
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / physiopathology*
  • Alzheimer Disease / prevention & control
  • Animals
  • Cognition Disorders / drug therapy
  • Cognition Disorders / physiopathology*
  • Cognition Disorders / prevention & control
  • Disease Models, Animal
  • Drug Design
  • Hippocampus / drug effects
  • Hippocampus / pathology
  • Hippocampus / physiopathology*
  • Humans
  • Memory / physiology
  • Memory Disorders / drug therapy
  • Memory Disorders / physiopathology*
  • Memory Disorders / prevention & control
  • Neural Pathways / drug effects
  • Neural Pathways / pathology
  • Neural Pathways / physiopathology
  • Nootropic Agents / pharmacology
  • Nootropic Agents / therapeutic use

Substances

  • Nootropic Agents